Capecitabine plus docetaxel combination therapy-Reference-Cited by-同舟云学术

Capecitabine plus docetaxel combination therapy

Published:2005 Issue:12 Volume:103 Page:2455-2465
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Verma Shailendra,Maraninchi Dominique,O'Shaughnessy Joyce,Jamieson Carol,Jones Stephen,Martín Miguel,McKendrick Joseph,Miles David,Twelves Chris,Hornberger John

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference22 articles.

1. Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial Results

2. Cost-effectiveness and evidence evaluation as criteria for coverage policy. Health Affairs. 2004; Web Exclusive. Available from URL: http://content.healthaffairs.org/cgi/content/abstract/hlthaff.w4.284 [accessed May 19, 2004].

3. Recommendations for Reporting Cost-effectiveness Analyses

4. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine

5. Markov Models in Medical Decision Making

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Docetaxel: An update on its molecular mechanisms, therapeutic trajectory and nanotechnology in the treatment of breast, lung and prostate cancer;Journal of Drug Delivery Science and Technology;2020-12

2. Economic evaluations of oral medications for breast cancer treatment in the U.S.: a systematic review with a focus on cost-effectiveness threshold;Expert Review of Pharmacoeconomics & Outcomes Research;2019-10-25

3. Reviewing the quality, health benefit and value for money of chemotherapy and targeted therapy for metastatic breast cancer;Breast Cancer Research and Treatment;2017-07-08

4. Phase I Study of Triweekly Nab-Paclitaxel Combined with S-1 in Patients with HER2-negative Metastatic Breast Cancer;Anticancer Research;2016-12-01

5. Cost–utility analyses of drug therapies in breast cancer: a systematic review;Breast Cancer Research and Treatment;2016-08-30